Ascletis Pharma Inc(2VJ) News

Date	Title
Feb 19	Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30